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Abstract
Tumors of central nervous system (CNS) account for a small portion of tumors 
of human body, which include tumors occurring in the parenchyma of brain and 
spinal cord as well as their coverings. The following chapter covers some new devel-
opment in some major brain tumors in both pediatric and adult populations, as well 
as some uncommon but diagnostic and management challenging tumors.
Keywords: gliomas, astrocytomas, oligodendrogliomas, mixed oligoastrocytomas, 
WHO (World Health Organization), WHO grades, medulloblastomas (MBs), 
midline diffuse astrocytoma, diffuse intrinsic pontine gliomas (DIPG), 
hemangioblastomas (HMBs), metastatic renal cell carcinoma (RCC), formalin-fixed, 
paraffin-embedded (FFPE), H3 K27M mutation, immunohistochemical (IHC) stain, 
fluorescence in situ hybridization (FISH)
1. Introduction
Tumors of central nervous system (CNS) include the tumors of the brain and 
spinal cord, as well as their covers. Those tumors are uncommon tumors, account-
ing for approximately 1% of all human body tumors. They can be divided into 
primary or secondary/metastatic tumors, benign or malignant tumors, based on 
the WHO classification; brain tumors are assigned into four grades, from Grade 1 
very benign tumor to Grade IV highly malignant tumors (see below). By location, 
those tumors can be divided into extra-axial tumors (outside brain/spinal cord 
parenchyma), such as meningiomas, and intra-axial tumors (inside brain/spinal 
cord parenchyma), such as gliomas. Diagnosis of brain tumors is primarily based 
on the WHO Classification of Tumors of CNS; this expert consensus scheme was 
first completed in 1979 and then revised in 1993, 2000, and 2016. This scheme is 
currently the most widely utilized by neuropathologists worldwide for typing and 
grading the CNS tumors [1]. Neoplasms, especially those malignant ones, are bio-
logically characterized by noncontrolled tumor cell proliferation; this uncontrolled 
growth is best explained by recently discovered EGFR (epidermal growth factor 
receptor) mutations, which mutations result in uncontrolled signal transduction 
downward to nuclei without ligand binding to the receptor and led to unlimited cell 
proliferation.
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During the last two decades, a lot of gene mutations are identified, especially 
in the oncology field, which has been helpful for the development of new genera-
tion of antitumor medication focusing on the mutated gene products. As a matter 
of fact, those target treatments have already archived tremendous successes in 
the oncology field. For example, gefitinib, erlotinib, and afatinib are the current 
targeted medications against EGFR-mutated non-small-cell lung cancers, which 
already show great clinical success.
The following chapter is going to review some development in brain tumors, 
especially the recent understanding of adult gliomas and pediatric medulloblas-
tomas, as well as some other uncommon tumors for their molecular diagnosis and 
genetic subgrouping.
2. Molecular diagnosis of adult gliomas
Glial tumors comprise approximately 25–30% of primary CNS tumors [1] and 
represent a spectrum ranging from low-grade, benign to the highly aggressive, 
malignant tumors. They are broadly classified by glial cell type of origin and deter-
mined by histology with or without the use of immunohistochemistry (IHC), which 
is then used to provide a WHO grade (see Table 1) [1]; however, histology has not 
been able to accurately predict response to treatment or clinical outcomes, and it is 
not uncommon for many of these tumors with nearly identical histologic features 
to have very different outcomes. As a result of these observations, and like many 
malignancies (lung and colorectal carcinoma for example), there has been increas-
ing interest in attempting to further classify these tumors based on their molecular 
expression. With that interest there is an increase in available published data 
regarding these molecular alterations and a subsequent increase in the availability 
of myriad testing modalities; some of which are now considered well established, 
while others are not. In an era of test utilization awareness and rising healthcare 
costs, this phenomenon frequently leads to confusion regarding which tests should 
be utilized, how those tests should be interpreted, and how they should be reported, 
in order to best guide treatment and predict outcomes in this patient population [2]. 
Table 1. 
Molecular genetic map for the development of adult gliomas.
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We will discuss here the well-established molecular concepts, touch briefly on the 
evolving molecular discoveries, and provide a testing algorithm (see Table 1).
Glioblastoma (GBM) is the most aggressive primary CNS malignancy, WHO 
Grade IV [1]. Despite decades of research and multiple new treatment modalities, 
little progress has been made in terms of substantial improvements of patients’ 
outcomes, with the average long-term survival being measured in months rather 
than years [3]. However, this research has illuminated a complex series of molecular 
pathways and events that is improving our understanding of the pathophysiology of 
this aggressive entity.
2.1 LOH 10q
Loss of heterozygosity (LOH) at chromosome 10q occurs with high frequency 
in both primary and secondary GBMs, occurring in both in approximately 60–80% 
of cases [4]. Although this is an interesting primary event in the development of 
GBM of either type, because of its high frequency, it is not useful in distinguishing 
one from the other. Instead, GBM is currently subclassified by its molecular altera-
tions into primary and secondary GBM, based on the presence or absence of IDH1/
IDH2 and/or TP53 mutations [4]. EGFR status is also being increasingly used in this 
context.
2.2 IDH1/IDH2
Isocitrate dehydrogenase-1 (IDH1) is an NADP-dependent enzyme found 
in the cytoplasm responsible for the conversion of isocitrate to α-ketoglutarate 
and thereby producing NADPH, which reduces reactive oxygen species. IDH2 
is similarly present in mitochondria. Their exact role in tumorigenesis is poorly 
understood; however, it is thought that mutations in this enzyme result in increased 
oxidative stress and subsequent carcinogenesis. It is therefore not surprising that 
this mutation is not found in primary GBMs, rather secondary GBMs that have 
progressed from a less aggressive tumor, and diffuse and anaplastic astrocytomas 
(WHO Grade II and III, respectively). IDH mutations are found with high fre-
quency in the majority of astrocytomas, oligodendrogliomas, mixed gliomas, and 
secondary GBMs but not in pilocytic astrocytomas or primary GBMs. The most 
common mutation in IDH1 is a point mutation (arginine to histidine at codon 132), 
termed IDH1-R132H. IDH2 mutations (IDH2 172) represent only 3–5% of IDH 
mutations and are more commonly found in oligodendrogliomas. IDH mutations 
have also shown an association with hypoxia-inducible factor 1 alpha (HIF1), 
associated with upregulation of vascular endothelial growth factor (VEGF). Recent 
study indicates that low-grade astrocytomas with wild-type IDH1 behavior as 
glioblastoma clinically, suggesting again the importance of IDH1 mutation status in 
gliomas. IDH1 mutation can be detected by IHC, and commercially available mouse 
antihuman monoclonal antibody by Dianova with clone name H09 is a favored 
antibody to IDH1 R132H by most neuropathologists.
Secondary glioblastomas confer a significantly better prognosis than those arising 
de novo (primary GBM), and occur in a younger age group with a history of pervious 
low grade gliomas [4]. Because primary and secondary GBMs cannot be distinguished 
morphologically, IDH1/2 mutation testing can be utilized for this task, allowing for 
better prognostication. IDH1/2 is commercially available as a reverse transcriptase 
PCR (RT-PCR) test. Although an IHC stain is available, it is not as sensitive to the less 
common variants of IDH1/2 mutation; however, it can be highly useful in the detec-
tion of single tumor cells in diffuse gliomas [5–7]. It is important to note that the role 
of IDH1/2 mutations in predicting response to therapy is still debated. It appears that 
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the mutation confers an increased response to radiation therapy, while others show an 
increased response with chemotherapy as well. Response appears to be multifactorial, 
dependent not only on the type of therapy, but also on the time of that therapy in rela-
tion to surgical resection [8]. Importantly, IDH mutations serve as a surrogate marker 
for secondary GBMs [9]. This testing should be performed in conjunction with TP53 
and Ki67 on all GBMs, and considered standard of care.
2.3 P53
P53 is a cyclin-dependent kinase responsible for tumor suppression through 
prevention of cell replication. Mutations in p53 in malignant tumors are well 
established in the literature, with greater than 50% of cancers showing p53 loss of 
function mutations [10]. P53 is more commonly a missense mutation that results in 
accumulation of the protein in the cytoplasm, resulting in diffuse, strong nuclear 
staining by IHC; however, alternate mutations in p53 can show complete absence of 
staining or cytoplasmic staining only, whereas the wild type (unmutated) p53 will 
show weak to moderate, patchy positivity [11].
Most tumors that express p53 mutations typically have a more aggressive course 
than those that do not; however, this relationship has not been established in GBMs. 
Currently, no statistically significant difference has been established that GBMs 
with p53 mutations have a worse prognosis than those that do not [12]. The utility 
of p53 in GBMs, similar to IDH1/2 mutation status, is as additional evidence of a 
secondary GBM, rather than a primary GBM, as p53 mutations are far less frequent 
in primary GBMs, and, when present, likely represent secondary or late events 
associated with increasing genetic instability [4].
2.4 Epidermal growth factor receptor (EGFR)
EGFR is a member of the transmembrane tyrosine kinase receptor family that 
activates MAPK and PIK3 pathways resulting in cell proliferation. EGFR testing 
started to gain particular popularity due in part to the development of tyrosine 
kinase inhibitors (TKIs) and after a 2010 study by Verhaak et al. that attempted to 
further subclassify GBMs based on multiple molecular markers [15]. EGFR amplifi-
cation confers more aggressive behavior and poorer outcomes, autophosphorylating 
the PIK3 pathway, leading to increased growth, angiogenesis, metastatic potential, 
and reduced apoptosis [16]. In contrast to secondary GBMs, epidermal growth 
factor receptor (EGFR) overexpression has been demonstrated in 36% of primary 
GBMs, with 70% of those showing amplification. It exists most commonly as the 
mutation EGFR variant 3 (EGFRvIII), which has deletion of exons 2 and 7 [17]. 
EFGRvIII mutation testing is performed with RT-PCR [17]. Unlike other malignan-
cies where tyrosine kinase inhibitor (TKI) immunotherapy has shown wide suc-
cesses, GBMs frequently do not respond, showed only a partial response, or develop 
rapid resistance to TKIs. This most often attributed to PTEN loss earlier in the 
EGFR pathway [4]. EGFR amplification or mutation in this context can be utilized, 
when present, as further support of a primary GBM over a secondary GBM.
In addition to the discovery of multiple molecular alterations in MET, PDGFRA, 
NF1, PTEN, PIK3 and CDKN2A/B, and several others, studies have discovered alter-
ations of several microRNAs, which are also a field of current study. Importantly, 
none of these have been well established in terms of either their prognostic sig-
nificance or their impact on treatment response, and several studies have shown 
contradictory results. This likely can be attributed to the marked heterogeneity of 
glial tumors, particularly GBMs. It is not currently recommended to add these mark-
ers to a broader profile until their clinical significance can be better established.
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2.5 1p/19q co-deletion
Chromosome arms 1p and 19q deletions are the most characterized genetic aber-
rations of oligodendrogliomas, with up to 80% of classical oligodendrogliomas (WHO 
Grade II) and 60% of anaplastic oligodendrogliomas (WHO Grade III) [18, 19].  
Although it seems unclear what impact these deletions have on cellular function, 
there are two identified roles for testing these deletions: the first is as a diagnostic 
marker for oligodendroglial tumors and the other as an indicator of response to 
treatment. One study demonstrated that the presence of complete or partial co-
deletion of 1p and 19q conferred a significantly increased response to chemother-
apy, and prolonged disease-free survival time, compared with those tumors with 
deletion of only one or the other chromosomal arm, regardless of histologic subtype 
[20], consistent with other studies, including mixed tumors. Due to the significant 
clinical implications for the presence of this gene, 1p/19q co-deletion testing should 
be performed on all glial tumors with or without oligodendroglial features since a 
small percentage (5%) of morphological astrocytomas are with 1p/19q co-deletion, 
which may confer a slightly better prognosis for the patients. Testing is available by 
both FISH and for LOH by real-time PCR. Evaluation of both chromosomal arms in 
their entirety is recommended due to molecular variability.
2.6 MGMT methylation
O6-methylguanine-DNA methyltransferase (MGMT) codes for MGMT repair 
protein, and methylation of this gene, which results in suppression and decreased 
expression of the MGMT protein, confers a significant survival benefit in patient 
treated with combined radiation and temozolomide therapy. MGMT methylation 
occurs in all types of gliomas and with frequency in primary and secondary GBMs 
and oligodendrogliomas (60–93%). In predicting a positive response to treatment, 
MGMT methylation also predicts an increased survival benefit. In lower-grade glio-
mas, MGMT methylation confers an increased response to radiation monotherapy, 
which is not well understood [9].
Methylation-specific PCR is the testing modality of choice and is widely avail-
able. An alternative is pyrosequencing, which shows high sensitivity, but is now less 
frequently used. Other testing modalities, such as western blot and IHC, have fallen 
into disuse due to issues with false-positive results.
Table 1 summarizes the current understanding of tumorigenesis for adult 
gliomas.
3.  Molecular diagnosis of diffuse midline gliomas with H3 K27M 
mutation
It has been recognized for almost 20 years among pediatric neuro-oncologists 
that neuroimaging study defined diffuse intrinsic pontine gliomas (DIPG) had a 
very poor prognosis independent of histological grade (if biopsied). In that case, 
biopsy is most of the time considered unnecessary until recent identification of 
potential drug targets for individualized therapy has led to reevaluation of this 
approach [22]. Recent genomic analysis has demonstrated that specific genetic 
alterations drive distinct subsets of glial neoplasm of the central nervous system, 
dependent not only on tumor-type but also on the site of origin and patient age. 
Like this diffuse midline gliomas, with somatic mutations of the H3F3A and 
HIST1H3B gene encoding the histone H3 variants, H3.3 and H3.1, were recently 
identified in high-grade gliomas arising in the thalamus, pons, and spinal cord of 
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children and young adults; those tumors are named as diffuse midline gliomas with 
H3 K27M mutation [23].
Brainstem tumors affect primarily children and young adults. Each year, around 
300–400 cases of brainstem tumors are diagnosed in the United States, and diffuse 
intrinsic pontine glioma (DIPG) accounts approximately 80% of these tumors [24]. 
DIPG has been recently categorized by WHO classification as high-grade (Grade 
IV) diffuse midline gliomas with H3 K27M mutation. It carries a poor prognosis, 
and only 1% of the patients live 5 years after diagnosis.
Clinically, diffuse midline gliomas result in brainstem dysfunction and the 
obstruction of cerebrospinal fluid (CSF) flow. The patients suffer from difficulty 
in ocular movements, weakness of facial muscles, sudden hearing problem, swal-
lowing difficulty, muscle spasticity, clonus, and bladder dysfunction, along with 
multiple cranial neuropathies and ataxia.
Diagnosis of diffuse midline gliomas is initiated through imaging primarily by 
MRI scans indicating hypointense (T1) or hyperintense (T2) lesions, enhancing 
or non-enhancing after administration of contract agents. Biopsy is a standard 
procedure for establishing the molecular and histopathological diagnoses. This 
tumor shows many histopathological features of glioblastoma such as pseudopali-
sading necrosis and microvascular proliferation, in addition to H3 K27M positive by 
immunohistochemical (IHC) stain (Figure 1).
Unlike many other adult gliomas, debunking surgery, with gross total resection 
(GTR) of the tumor, is not a treatment of choice for diffuse midline gliomas, mainly 
due to the location of the tumors. The brainstem regulates critical bodily functions, 
and therefore surgical resection without damaging the vital area of the brainstem 
is almost impossible. Surgery is indicated only for biopsy of the tumor and to 
relieve the hydrocephalus that may happen in a small fraction of cases. Currently, 
patients are treated primarily with radiation and adjuvant chemotherapy with 
temozolomide.
In diffuse midline gliomas with H3 K27 mutation, lysine in 27th position of 
tail of Histone 3.3 is replaced by methionine. Histones are the alkaline protein 
that provides a scaffold, around which DNA wraps. Solomon and colleague have 
observed that H3K37M mutation in pontine gliomas occurred at a much younger 
age (median 7 years of age) than gliomas of the thalamus (median age, 24 years) 
or spinal cord (median age, 25 years) [23]. The H3 K27M-positive gliomas have 
also been reported in adult in the brainstem [25]. High-grade gliomas with H3 
K27M mutation may have additional mutations (WHO, 2016). These mutations are 
observed to occur in the critical genes, regulating cell divisions including cell cycle 
checkpoints and chromatin remodeling. The most frequent additional mutation 
noted is tumor suppressor p53, which is noted in an estimated half of the H3 K27M 
Figure 1. 
(A) Grade IV midline glioblastoma and (B) IHC + for H3 K27M mutation.
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midline gliomas. Amplification of platelet-derived growth factor alpha (PDGFRA), 
critical for cell survival and proliferation, is observed in about 30% of the H3 K27M 
tumors. Cyclin-dependent kinases 4 and 6 are reported to be amplified in 20% of 
the tumors, and homozygous deletion of cyclin-dependent kinase inhibitor 2A/2B 
is noted in 5% of the H3 K27M gliomas. Mutation of activin A receptor type-1 
(AVCR1) is noted in 20% of H3 K27M gliomas. A mutation of protein phosphatase 
1D (PPM1D) and amplification of MYC/PVT1 may present separately, in 15% of 
the H3 K27M gliomas [1]. In addition, histone H3 K27M mutation is found mutually 
exclusive with IDH1 mutation and EGFR amplification, rarely co-occurred with 
BRAF-V600E mutation, and was commonly associated with p53 overexpression, 
ATRX loss (except in pontine gliomas), and monosomy 10 [23].
These mutations could provide us with a better understanding of the disease 
process and could potentially lead to the development of a better treatment strategy 
for this deadly disease. As a matter of fact, at least two clinical trials are underway 
with small molecule inhibitor of the histone demethylase, which showed some 
promising result [23].
4. Molecular subgroups of medulloblastomas
Medulloblastoma is the most common malignant brain tumor of cerebellum in 
childhood, although it rarely happens in adult patients, too. It is an embryonal neuro-
epithelial tumor arising in the cerebellum or dorsal brainstem, which is a major cause 
of morbidity and mortality in pediatric brain tumor patients [27, 28], and was designed 
as WHO Grade IV neoplasm [1]. Histologically, medulloblastoma is a prototypical 
embryonal tumor, consisting of densely packed small round undifferentiated blue 
tumor cells with mild to moderate nuclear pleomorphism and a high mitotic count, 
mostly with Homer-Wright rosettes, and shows different morphological variants, such 
as desmoplastic/nodular, large cell, and anaplastic, etc., with predominantly neuronal 
differentiation and tendency to metastasize via CSF pathways [1] (Figures 2 and 3).
4.1 Morphologic features of medulloblastomas
Several morphological variants of MBs are recognized, alongside the classic 
tumor: desmoplastic/nodular MB, MB with extensive nodularity, and large-cell/
anaplastic MB. A dominant population of undifferentiated cells with a high 
nuclear-to-cytoplasmic ratio and active mitotic figures is a common feature [1] 
(Figures 2 and 3). Classic MB composed of sheets of undifferentiated small blue 
Figure 2. 
Histopathology of MBs. (A) Classic type, 70%; (B) nodular, 10%; (C) extensive nodularity, 3%; and (D) large 
cell/anaplastic, 15% (arrow nuclear molding, blue; wrapping, red).
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tumor cells with Homer-Wright rosette formations and/or palisading tumor cells 
forming a pseudoglandular feature, easily found mitoses and apoptosis. Other 
histological variants include desmoplastic MB, which contains abundant reticulin 
and collagen, characterized with nodular reticulin-free zones (pale islands). The 
nodules have reduced cellularity, a rarified fibrillar matrix and marked nuclear 
uniformity. A rare histologic type of MB is the so-called large-cell MB, which is 
composed completely or partially of cells with large, round nuclei and prominent 
nucleoli, commonly with large areas of necrosis. The large-cell MB sometimes 
resembles the rhabdoid/atypical teratoid (RT/AT) tumors of cerebellum, but its 
cytoplasm lacks globular hyaline inclusions and is diffusely reactive for synapto-
physin, neurofilament protein, and vimentin and negative for epithelial membrane 
antigen, cytokeratins, and smooth-muscle actin by immunohistochemical (IHC) 
stains [1]. Most often associated with large-cell MB is anaplastic MB, which is 
characterized by angular, crowded, pleomorphic nuclei in large cells, sometimes 
with nuclear molding and wrapping (Figure 3), mitosis, and apoptosis, as well as 
prominent nucleoli. It has been noted for a long time that morphology of MBs was 
related to patient’s prognosis and that those MBs with extensive nodularity are with 
better prognosis, while the large-cell/anaplastic MBs are usually associated with 
worse clinical outcomes (Figure 1).
Additional study indicates that poor survival outcome was significantly associ-
ated with chromosome 17p loss (loss of tumor suppressor) and high expression of 
oncogenes c-myc (MYCC) or N-myc (MYCN) [1].
Due to the highly heterogeneous nature of the MB, and complication caused by 
aggressive treatments, a more specific subgrouping of this tumor is becoming more 
and more important for clinical judgment.
Molecular studies from multiple groups around the world found that medullo-
blastoma is not a single disease but comprises a collection of clinically and molecu-
larly diverse subgroups. Current consensus made in a 2010 meeting at Boston agrees 
that there are four principal subgroups of medulloblastomas [27, 28] termed as 
WNT, SHH, Group 3, and Group 4.
Two of these subgroups, characterized by either activated WNT or SHH 
signaling pathway, are thought to play prominent roles in the pathogenesis. Two 
other non-WNT/non-SHH groups are more closely related to each other and even 
produced additional different numbers of subgroups within these groups of MBs, 
pending additional evidence to further classify them [27, 28].
Figure 3. 
Histopathology of MBs. (A) Homer Wright rosettes and (B) nuclear wrapping (hugging), arrow, in large-cell/
anaplastic MBs.
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4.1.1 MB, WNT subgroup
The best known subgroup of the medulloblastoma is the WNT subgroup due to 
its very good long-term prognosis, compared to other subgroups. WNT indicates 
the wingless signaling pathway.
WNT medulloblastomas are characterized by upregulation of the canonical 
WNT signaling pathway, which results in translocation of β-catenin to the nucleus. 
About two-thirds harbor a CTNNB1 mutation. Mutations in other pathways, such 
as APC and AXIN1, have been reported in the absence of a CTNNB1 mutation but 
are much less frequent [27]. The extent of β-catenin nuclear immunoreactivity in 
these WNT pathway MBs always amounts to more than a third of the total tumor 
area and is clearly different from the situation where very few scattered β-catenin 
nucleopositive cells, representing less than 2% of tumor cells, are evident. Assays 
for CTNNB1 mutation and monosomy 6, which occurs in nearly all WNT pathway 
MBs, have helped to establish the status of tumors in these immunohistochemical 
categories [27]. There is a close association between a WNT pathway immunophe-
notype and CTNNB1 mutation or monosomy 6, predicting a good outcome for 
medulloblastomas with these genetic abnormalities [27].
More than 90% of WNT subgroup medulloblastoma patients achieved long-term 
survival, with those patients whose death is due to more complications of therapy or 
secondary tumors rather than due to recurrent WNT medulloblastomas. Germline 
mutations of the WNT pathway inhibit APC predispose to Turcot syndrome, 
which includes a proclivity to medulloblastoma; in addition, somatic mutations of 
CTNNB1 encoding  β -catinin have been found in sporadic medulloblastomas [27]. 
These strong germline and somatic genetic data support an etiological role for 
canonical WNT signaling in the pathogenesis of this group of tumors and lead to 
the nomenclature of “WNT subgroup of medulloblastomas.”
Almost all WNT medulloblastomas have classic histology, which often 
described as having CTNNB1 mutations, with nuclear labeling for β-catenin by 
immunohistochemical stain, and monosomy 6 (deletion of one copy of chromo-
some 6 in tumor cells). Medulloblastomas with large-cell/anaplastic features have 
also been reported in the WNT subgroup, although they appear to maintain the 
excellent prognosis associated with the WNT subgroup. Which of monosomy 6,  
nuclear staining for β-catenin, mutation of CTNNB1, immunohistochemical 
staining for DKK1, or a transcriptional signature that clusters with other WNT 
tumors should be used as a gold standard for the diagnosis of WNT medul-
loblastomas awaits further validation on large cohorts of well-characterized 
medulloblastomas.
WNT-activated MBs account for approximately 10% of all MBs, most of them 
present in children aged between 7 and 14 years, but they can also occur in young 
adults. Genetically, besides CTNNB1, genes that are recurrently mutated in WNT-
activated MBs include TP53, SMARCA4, and DDX3X [1].
4.1.2 MB, SHH subgroup with TP53 mutant
The SHH group of MBs are named after the sonic hedgehog signaling pathway. In 
large series of tumors, SHH-activated MBs tend to have similar transcriptome, meth-
ylome, and microRNA profiles. SHH pathway activation in TP53-mutant tumors is 
associated with amplification of GLI2, MYCN, or SHH. Mutations in PTCH1, SUFU, 
and SMO are genetically absent. Large-cell/anaplastic morphology and chromosome 
17p loss are also common in SHH-activated and TP53-mutant tumors. Patterns of 
chromosome shattering known as chromothripsis are often present.
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SHH-activated tumors account for approximately 30% of all MBs and originate 
from rhombic lip-derived cerebellar granule neuron precursors. SHH-activated and 
TP53-mutant MBs are rare and generally found in children aged 4–17 years. Clinical 
outcomes in patients with SHH-activated and TP53-mutant tumors are very poor [1].
4.1.3 MB, SHH subgroup, with TP53 wild type
SHH pathway activation in TP53 wild-type tumors can be associated with 
germline or somatic mutation in the negative regulations PTCH1 or SUFU, as 
well as activating somatic mutations in SMO or (rarely) amplification of GLI2. 
Desmoplastic/nodular MBs and MBs with extensive nodularity are always included 
in the SHH-activated group, but tumors with a SHH signaling pathway can also 
have a classic or large-cell/anaplastic morphology, particularly in older children. 
Patients with SHH-activated and TP53 wild-type MBs are generally children aged 
<4 years, adolescents, or young adults. In addition to genetic changes activating 
SHH signaling, mutations in DDX3X or KMT2D and amplification of MYCN or 
MYCL are sometimes seen, as are deletions of chromosomal arms 9q, 10q, and 14q. 
Clinical outcomes in patients with SHH-activated tumors are variable [1].
4.2 Epidemiology
Research data from 1973 to 2007 suggested MB incidence rates of 0.6 cases per 
1 million children aged 1–9 years and 0.6 cases per 1 million adults aged >19 years. 
SHH-activated MBs in general show a bimodal age distribution, being most com-
mon in infants and young adults, with a male-female ratio of approximately 1.5:1. 
In contrast, SHH-activated and TP53-mutant tumors are generally found in chil-
dren aged 4–17 years. In one study including 133 SHH-activated MBs, 28 patients 
(21%) had a TP53 mutation, and the median age of these patients was approxi-
mately 15 years [1].
4.2.1 Groups 3 and 4/non-WNT and non-SHH groups
Groups 3 and 4 MBs are usually called “the non-WNT/non-SHH groups.” They 
share some of the similarities in both clinical presentation and molecular profiling. 
Most tumors in these groups display classical histology. The large-cell/anaplastic 
and desmoplastic histologies are present but at a lower frequency. The age of onset 
is distributed in both groups with most patients are children; they are relatively 
uncommon in infants and adults. Although both groups have similar frequency 
of metastasis, Group 3 shows poor prognosis, while Group 4 shows intermediate 
prognosis. Non-WNT and non-SHH tumors account for approximately 60% of all 
MBs and typically have classic histopathological features [1].
One characteristic similarity between Groups 3 and 4 is both subgroups are 
enriched for expression of genes involved in photoreceptor differentiation, 
and they express high level of OTX2 and FOXG1B, well-known oncogenes of 
MB. However, Group 3 is distinguished by its enriched gene signatures function-
ing in cell cycle, protein biosynthesis, glutamate receptor signaling, and p38 
mitogen-activated protein kinase (MMAPK) pathway, while Group 4 is overrep-
resented by genes involved in neuronal differentiation, development, cytoskel-
eton organization, etc.
In addition, isochromosome 17q (I17q) represents the most common structural 
abnormality in Groups 3 and 4. Other chromosomal alteration identified in these 
subgroups includes gain of 7 and 18q and loss of 8 and 11q. The major difference 
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between these two groups is the enrichment of MYC amplification in Group 3, 
which is very rarely observed in Group 4, as well as in WNT and SHH. Another dif-
ference is the enrichment of chromosome X loss in Group 4, found in 80% female 
MBs in Group 4.
The signaling pathway or biological programs driving the tumorigenesis of 
Groups 3 and 4 still remain largely unknown, although some reports suggest that 
disruption of chromatin genes associated with histone methylation may be a critical 
event driving Groups 3 and 4 tumor developments.
4.3  Medulloblastoma molecular subgroups: immunophenotypes and 
histopathological associations
After multigroup extensive researches, the development and validation 
of immunohistochemical stains to define molecular subgroups of MBs finally 
archived, with 4 immunohistochemical staining marker identified in order to MBs 
subgrouping, which can be used in FFPE tissue and greatly improve the routine 
pathological diagnosis process for these types of tumors. Four immunostaining 
markers were selected for pathological subgrouping of MBs: they are β-catenin, 
GAB1, filamin A, and YAP1 [27].
4.3.1 SHH pathway MBs
Combined immunoreactivities for GAB1, filamin A, and YAP1, indicating a SHH 
profile, were found in 31% of MBs, including all desmoplastic tumors. Desmoplastic 
MBs constituted 54% of SHH pathway tumors, and classic and large-cell/anaplastic 
tumors contributed 29 and 17%, respectively. While non-desmoplastic SHH tumor 
generally showed widespread and strong immunoreactivities for GAB1, YAP1, and 
filamin A, all three types of desmoplastic tumors displayed stronger staining for 
these proteins within internodular regions. Immunoreactivities for filamin A and 
YAP1 in SHH tumors were always strong and generally widespread. This was not 
always the situation for GAB1 immunoreactivity; no more than weak cytoplasmic 
staining for GAB1 was seen in a few non-desmoplastic SHH tumors (n = 6). These 
tumors were all strongly immunopositive for filamin A and YAP1, which acted to 
confirm the SHH phenotype [27].
4.3.2 WNT pathway MBs
Antibodies to β-catenin for identifying WNT tumors effective on formalin-fixed 
and paraffin-embedded (FFPE) tissue are well established in the diagnostic labora-
tory [27]. Widespread intermediate or strong cytoplasmic β-catenin immunore-
activity was a feature of nearly all MBs in the series; very few showed only patchy 
weak cytoplasmic staining for this antigen. WNT pathway MBs were identified by 
nuclear, as well as cytoplasmic, immunoreactivity for β-catenin (Figure 4). WNT 
pathway MBs defined by these types of nuclear β-catenin immunoreactivity also 
express filamin A. Typically, this was patchy staining and less intense than that seen 
in SHH tumors. Strong and widespread nuclear immunoreactivity for YAP1 was 
also a feature of WNT pathway tumors. This distinctive combination of β-catenin, 
filamin A, and YAP1 immunoreactivities robustly confirmed the status of MBs in 
this molecular subgroup. WNT tumors contributed 14% of all MBs in this study. 
Nearly all WNT pathway MBs were classic tumors. Large-cell/anaplastic tumor 
(n = 2, 6%) was exceptional among WNT tumors, while desmoplastic MBs were not 
represented [27].
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4.3.3 Non-SHH/WNT MBs
MBs (N = 130, 55%) falling outside the SHH and WNT categories displayed 
cytoplasmic, but not nuclear, immunoreactivity for β-catenin. Tumor cells were 
negative for GAB1 and YAP1. In general, tumors in this category were also immu-
nonegative for filamin A, though very weak and patch immunoreactivity for this 
antigen was evident in rare non-SHH/WNT MBs (n = 9), which were classified as 
such on the basis of the panel of immunoreactivities. Intrinsic vascular elements 
were immunopositive for YAP1 and filamin A, providing an internal control. This 
subgroup of MBs was dominated by classic tumors (92%), including all non- 
desmoplastic nodular tumors and all but one MB that contained small clusters of 
densely packed neurocytic cells, the exception being a WNT tumor. Large-cell/
anaplastic tumors made up the remainder (n = 11) [27].
4.3.4 Metastatic MBs
Despite four subgroups, metastatic MBs exist among all subgroups although the 
incidence of metastatic dissemination is higher in Group 3 and 4 than WNT and 
Figure 4. 
β-Catenin IHC stain with both nuclear and cytoplasmic positive (A and C), GAB1 stain positive (B), YAP1 
(D), and filamin A (E).
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SHH [33]. Metastatic MBs occur in approximately 40% of all MBs at diagnosis and 
are associated with poorer prognosis [34]. In 2001, McDonald et al. [35] identi-
fied potential therapeutic targets, e.g., PDGFRα PDGFR for metastatic MBs using 
expression array analysis. However, Gilbertson and Clifford [36] found that the 
probe McDonald used for PDGFRα was PDGFRβ. They further demonstrated that 
PDGFRβ is overexpressed in metastatic MB. Then, Kohane and his co-workers did 
an interesting experiment and found that genomically, human MBs were closest 
to mouse P (postnatal) 1-P10 cerebella, and normal human cerebella were closest 
to mouse P30-P60. Metastatic human MBs were highly associated with mouse P5 
cerebella (non-metastatic human MB with mouse P7 cerebella). PDGFRα is highly 
expressed in P5; PDGFRβ in P7 [37]. However, which isoform of PDGFRs plays a role 
in metastatic MBs kept controversial. Ten years later, we demonstrated that PDGFRα 
inhibits while PDGFRβ promotes MB cell proliferation and cell survival as well as cell 
invasion [38], highlighting that PDGFRβ may serve as a potential therapeutic target 
for metastatic MBs and warrants further investigation, including clinical studies.
Table 2 summarizes the IHC staining for subgroups of MBs.
5.  Hemangioblastoma, metastatic renal cell carcinoma, and von Hippel-
Lindau disease
Hemangioblastoma (HMB) is a benign, slow-growing, WHO grade I tumor, 
most likely occurs in cerebellum, brainstem, and spinal cord. Most hemangio-
blastomas are cystic on neuroimaging with intramural nodule. Histologically, the 
tumor has two major components, one is tightly packed capillary small vessels, and 
another is so-called stromal cells with low-grade nuclei, foamy cytoplasm, and no 
prominent nucleoli. Mitosis and necrosis are absent. But some degenerative features 
are often present [1].
On the other hand, cerebellum is a favorite location for metastatic renal cell 
carcinoma (RCC). Histologically, most RCC has clear cytoplasm with rich vascular 
supply, but slightly higher-grade nuclei mostly have small nucleoli.
Due to the similarity in histology and the same preference location, 70% of 
HMBs occur in sporadic forms, while approximately 30% of HMBs are associated 
with the inherited von Hippel-Lindau disease. The VHL tumor suppressor gene is 
inactivated both in VHL-associated cases and in most sporadic cases [1].
Von Hippel-Lindau disease (VHL) is a familial disorder predisposing patients 
to cysts and hypervascular neoplasm of multiple organs, including the CNS, eye, 
kidneys, adrenal medulla, pancreas, inner ear/temporal bone, and epididymis.
VHL is an autosomal dominant disorder, with roughly 20% of patients present-
ing as sporadic cases with no family history. The VHL tumor suppressor gene maps 
to chromosome 3p25 and includes three highly conserved exons [31].
IHC marker IHC stain for MBs MBs subgrouping
WNT SHH Non-WNT/non-SHH
β-Catenin N+, C+, ¼ focal C+ C+
GAB1 Neg C+ Neg
Filamin A C+ C+ Neg
YAP1 N+, C+ N+, C+ Neg
N+, nuclear staining positive; C+, cytoplasmic staining positive; SHH, Sonic Hedgehog.
Table 2. 
Subgrouping MBs by immunohistochemical stains.
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VHL-associated disease includes [31] the following:
• Retinal hemangioblastomas (40–60%)
• CNS hemangioblastomas (60–80%)
• Endolymphatic sac tumor (2–11%)
• Pheochromocytomas (10–25%)
• Pancreatic cysts or islet tumors (60–80%)
• Renal cysts and RCCs (30–60%)
• Papillary cystadenomas of the epididymis (20–60%)
Solitary and especially multiple HMBs are diagnostic hallmarks of VHL. Roughly 
75% are infratentorial, mainly involving the cerebellum. The rest of them are found 
Figure 5. 
Hemangioblastoma, H&E stain ×200, with low-grade nuclei and foamy stromal cells (A); metastatic RCC 
with clear cytoplasm, larger nuclei, and prominent nucleoli H&E stain ×400 (B); and RCC is immunoreactive 
for CD10 (C) and cytokeratin (D).
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in the spinal cord, brainstem, and lumbosacral nerve roots. Supratentorial HMBs 
are extremely rare. Of interest, only about 25–30% of cerebellar HMBs are seen in 
VHL patients, whereas this fraction rises to 80% in the spinal cord [1].
It is may be those two tumors share the same chromosome locus of 3p25; they 
have some histological overlapping as well as the same preference of anatomic 
location (cerebellum); HMB and metastatic RCC are two tumors almost always 
request differentiation diagnosis, since one is benign and another is malignant, 
both carry different prognoses, and this two tumors become “forever differential 
diagnosis” for most diagnostic neuropathologists. Luckily, a simple small panel of 
immunohistochemical (IHC) stain would easily resolve this puzzle. HMB is nega-
tive for cytokeratin but positive for inhibin and 2D40, while RCC will be positive for 
cytokeratin, CD10, and PAX-8 and negative for inhibin [31] (Figure 5).
6. Summary
Research work in the last two decades discovered lots of genetic alterations in 
human brain tumors. More work will be done to further facilitate the diagnosis 
and classification. A recent proposal is suggested by using the epigenomics, like 
methylation status, to enhance brain tumor classification [32]. A new clinical trial 
with medication focusing on the IDH1 mutation is underway now; as more and 
more research data collected, we believe more effective treatment options will be 
developed in the near future. For a more detailed review on the molecular neuropa-
thology of brain tumors, please refer to Ref. [39].
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